<DOC>
	<DOCNO>NCT01059825</DOCNO>
	<brief_summary>MK-8835-016 ( B1521006 ) design evaluate safety efficacy investigational drug , ertugliflozin ( MK-8835 , PF-04971729 ) participant Type 2 diabetes mellitus . Participants study receive 1 6 treatment 12 week include 1 treatment approve drug ( sitagliptin ) treatment Type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study Of Safety And Efficacy Of Ertugliflozin ( PF-04971729 , MK-8835 ) In Participants With Type 2 Diabetes ( MK-8835-016 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients type 2 diabetes stable dos background medicine management diabetes ; age 1870 year ; body mass index 2345 kg/m2 Patients type 1 diabetes , heart attack stroke last 6months , uncontrolled blood pressure , significant kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>safety efficacy study ertugliflozin ( PF-04971729 , MK-8835 )</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>